Zhejiang University: Carcinoma trials
The registry lists 30 Carcinoma studies with Zhejiang University as lead sponsor. 7 are open to participants now and 0 have results posted.
Phase 1 6Phase 2 13Phase 3 1No phase 12(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT06995105Phase 1/2
- Efficacy and Safety of Liver Transplantation for Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: a Single-arm, Multicenter, Prospective Study (HCC-BDTT in LT)Not yet recruitingNCT06928415
- Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid CarcinomaNot yet recruitingNCT06848920Phase 2
- Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT06461624Phase 1
- A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid TumorsNot yet recruitingNCT06383507Phase 1
- Impact of "No-touch" Technique on the Outcome of Liver Transplantation for Hepatocellular CarcinomaNot yet recruitingNCT06331273
- Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular CarcinomaNot yet recruitingNCT06331260
- a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC StudyActive, not recruitingNCT06472635
- Survival Analysis: TACE vs. Combination Therapy in HCCCompletedNCT06261138
- Prognostic Models for HCC Based on Tumor MicronecrosisStatus unknownNCT05837065
- HCC Staging Modified by Tumor MicronecrosisCompletedNCT05739110
- Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine CarcinomaCompletedNCT05714722
- Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular CarcinomasCompletedNCT05352204
- Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular CarcinomaStatus unknownNCT05312216Phase 2
- A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionStatus unknownNCT04981665Phase 2
- Perioperative Therapy for Hepatocellular CarcinomaTerminatedNCT04653389Phase 2
- AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular CarcinomaStatus unknownNCT04368182Phase 1
- Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCCStatus unknownNCT04174781Phase 2
- 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3CompletedNCT03980288Phase 1
- A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery RecurrenceTerminatedNCT03945799Phase 1/2
- Liquid Biopsy-based Monitoring System for Relapse of HCC After Liver Transplantation: A Multi-center and Prospective StudyStatus unknownNCT03708705
- Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular CarcinomaStatus unknownNCT03668158
- Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver TransplantationWithdrawnNCT02580253Phase 2
- Surgery With HIPEC in Treating Patients With a High Risk of Developing Colorectal Peritoneal CarcinomatosisCompletedNCT02179489Not applicable
- Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1WithdrawnNCT02129322Phase 2
- Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular CarcinomaCompletedNCT02109146Phase 3
- Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of EsophagusWithdrawnNCT02041819Phase 2
- Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal CarcinomaWithdrawnNCT02034968Phase 2
- Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of EsophagusWithdrawnNCT02033538Phase 2
- Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal CarcinomaWithdrawnNCT02011594Phase 2